Study of Metformin Effects on Brain White Matter in Young Adults with Early Phase Psychosis Using Different Cannabis Potencies

What this Trial Is About

Researchers are studying young adults aged 18 to 25 with early phase psychosis EPP to understand how different levels of cannabis potency affect brain white matter. The study focuses on three groups based on cannabis use high potency over 15% THC, low potency under 15% THC, and minimal or no cannabis use. The goal is to see if metformin, a medication already used to manage side effects of antipsychotic drugs, can influence changes in white matter linked to cannabis use in these individuals. All participants will take metformin daily for six months while continuing their usual antipsychotic treatment. They will attend visits at the start of the study, at three months, and at six months. During these visits, participants will complete questionnaires on substance use and mental health, and undergo cognitive tests. MRI scans will be performed at the beginning and end of the study to assess brain changes. Throughout the study, researchers will collect detailed information about cannabis and other substance use, symptom severity, cognitive function, and brain imaging results. They will monitor adherence to metformin treatment and evaluate changes over time in cannabis use, white matter structure, and cognitive abilities. The study aims to test the feasibility of this approach to guide future research and treatment development in young adults with psychosis and cannabis use.

Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis